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Abstract
Uveal melanoma is an aggressive cancer that metastasizes to the liver in about half of the patients, with a high lethality rate.
Identification of patients at high risk of metastases may provide indication for a frequent follow-up for early detection of
metastases and treatment. The analysis of the gene expression profiles of primary human uveal melanomas showed high
expression of SDCBP gene (encoding for syndecan-binding protein-1 or mda-9/syntenin), which appeared higher in patients
with recurrence, whereas expression of syndecans was lower and unrelated to progression. Moreover, we found that high
expression of SDCBP gene was related to metastatic progression in two additional independent datasets of uveal melanoma
patients. More importantly, immunohistochemistry showed that high expression of mda-9/syntenin protein in primary
tumors was significantly related to metastatic recurrence in our cohort of patients. Mda-9/syntenin expression was
confirmed by RT-PCR, immunofluorescence and immunohistochemistry in cultured uveal melanoma cells or primary tumors.
Interestingly, mda-9/syntenin showed both cytoplasmic and nuclear localization in cell lines and in a fraction of patients,
suggesting its possible involvement in nuclear functions. A pseudo-metastatic model of uveal melanoma to the liver was
developed in NOD/SCID/IL2Rc null mice and the study of mda-9/syntenin expression in primary and metastatic lesions
revealed higher mda-9/syntenin in metastases. The inhibition of SDCBP expression by siRNA impaired the ability of uveal
melanoma cells to migrate in a wound–healing assay. Moreover, silencing of SDCBP in mda-9/syntenin-high uveal
melanoma cells inhibited the hepatocyte growth factor (HGF)-triggered invasion of matrigel membranes and inhibited the
activation of FAK, AKT and Src. Conversely syntenin overexpression in mda-9/syntenin-low uveal melanoma cells mediated
opposite effects. These results suggest that mda-9/syntenin is involved in uveal melanoma progression and that it warrants
further investigation as a candidate molecular marker of metastases and a potential therapeutic target.
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Introduction
Uveal melanoma is the most common primary intraocular
tumor in adults with an incidence rate of about 7 new cases per
one million individuals each year [1,2] About 50% of patients
develop metastases, mostly to the liver, within ten years from
diagnosis and their median survival is 5 to 7 months after detection
of metastatic lesions. The specific tropism of metastatic spreading,
together with the existence of specific genetic and molecular
markers of uveal melanoma, indicate that it is a distinct tumor
from the more common cutaneous melanoma [3]. Despite the
improvements in diagnosis and the development of more effective
local therapies for primary tumors, the rate of metastatic death
remains unchanged. Metastases are usually detected 2 to 5 year
after ocular treatment and are frequently resistant to chemother-
apy [4]. Therefore it seems important to identify high-risk patients
at the time of the initial diagnosis for early detection and treatment
of metastatic disease or for the administration of adjuvant therapy.
A great effort has been made to understand the biological
mechanisms involved in the spreading and growth of uveal
melanoma metastases and to discover new prognostic markers.
Hepatocyte growth factor/scatter factor (HGF) [5–7], Insulin-like
growth [8] and Stem cell factor [9–11] receptors have been
involved in metastatic progression of uveal melanoma. In addition,
the chemokine receptor CXCR4 was recently related to liver
homing of human uveal melanoma metastatic cells [12]. However,
the mechanisms responsible for hematogenous tumor dissemina-
tion and liver localization of metastases are still poorly understood.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29989A classification of uveal melanoma patients in two classes with
different prognosis (class-1 low-risk and class-2 high risk) has been
proposed on the basis of a specific tumor molecular signature
identified by gene expression profiling. [13,14]. As few as three
genes (PHLDA1, FZD6 and ENPP2) correctly predicted the class of
all tumor samples. Inhibitor of DNA binding 2, ID2, down
regulated in class-2 (i.e. high-risk) tumors, was later reported by the
same authors as the top class discriminating gene [14], the loss of
which causes an increase in the rate of liver metastasis in a
transgenic mouse model of ocular melanoma [15]. More recently,
the usage of a 15-gene PCR-based assay has been proposed as a
suitable method for the routine identification of the high-risk
phenotype [16].
In the search of possible molecular pathways involved in uveal
melanoma progression we focused our attention on SDCBP gene,
which we detected as a highly expressed gene through a
microarray analysis. SDCBP gene encodes for the syndecan-
binding protein syntenin-1, also known as melanoma differentia-
tion associated gene 9 (mda-9) [17]. Mda-9/syntenin is a
scaffolding-PDZ domain-containing protein with multiple biolog-
ical activities [18,19]. These include syndecan binding and
recycling [20,21] clustering of membrane receptors [22], intracel-
lular trafficking [23], Sox4 activation, and signal transduction
[24]. Mda-9/syntenin is able to influence the cell shape and also
the migration and invasion ability of different types of cancer cells,
including cutaneous melanoma [25–29] where high SDCBP
expression has been related to metastatic spreading [25].
In the present work we find an elevated expression of SDCBP by
gene expression profiling in a cohort of 29 primary uveal
melanomas. Moreover, high levels of mda-9/syntenin protein
are present in uveal melanoma cell lines, primary cultures and
biopsies of human primary tumors. Interestingly, high expression
of mda-9/syntenin protein is significantly related to metastatic
progression. In an animal model of pseudo-metastasis, mda-9/
syntenin expression is higher in metastases than in the primary
site, suggesting an active role of mda-9/syntenin in metastatic
spreading of uveal melanoma cells. This possibility is also
supported by the finding that mda-9/syntenin is involved in cell
migration of uveal melanoma cells in culture and in invasiveness
and activation of focal adhesion kinase (FAK), AKT and Src
triggered by HGF.
Materials and Methods
Cell cultures
The human uveal melanoma cell lines Mel 270, 92.1, OMM1
and OMM2.5 [30–31] were cultured in RPMI 1640 (Gibco-BRL,
Rockville, MD, USA) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin
at 37uC. Primary cultures were obtained from tumor biopsies,
upon approval of the institutional bioethics board and informed
written consent of the patients, by mechanical dissociation and
cultured in the medium above.
Tumor samples
Tissue samples were obtained from 29 uveal melanomas after
enucleation surgery upon approval of the institutional bioethics
board and informed written consent of the patients. Samples for
gene expression profiling were removed within 15 minutes after
surgery and conserved in RNAlater (Ambion, Monza, Italy) at
220uC until processing. Mean age of the patients (12 women and
17 males) was 64 (range 52–78). DNA copy number data were
available for 14 of these patients and the chromosome 3 monosomy
was inferred in the other patients from gene expression profile data
through a gene expression based classifier for monosomy of
chromosome 3. For the 14 tumor samples for which DNA copy
number alteration and gene expression profile data were available
we identified the genes whose expression levels were related to
chromosome 3 status. We calculated the centroids for monosomic
and disomic samples and classified the remaining 15 samples, for
which no copy number alteration data were available, according to
the distance from the centroid of each class (manuscript in
preparation). Chromosome 8 polysomy was evaluated by DNA
copy number in 14 patients and by FISH in the other patients.
Gene expression profile analysis
Tumor samples were homogenized in the tissue lyser Mixer Mill
(Qiagen, Hilden, Germany) in total RNA extraction lysis buffer
using RNeasy (Qiagen). RNA quality was assessed in the
BioAnalyzer (Agilent, St. Clara, CA). RNA Integrity Number
(RIN) was evaluated and only samples with RIN.or=7 were
considered acceptable. cDNA synthesis was performed using T7-
(dT)24 oligo primers and the Custom SuperScript Double-
Stranded cDNA Synthesis Kit (Invitrogen, Irvine, CA, USA).
Double stranded cDNAs were extracted with phenol-chloroform-
isoamyl alcohol (25:24:1), ethanol precipitated, and used to
prepare cRNAs using the Bioarray High Yield RNA Transcription
Kit (Affymetrix, Santa Clara, CA, USA) according to the
manufacturer’s instructions. cRNAs were purified using the
RNeasy Mini Kit (Qiagen), controlled by agarose gel electropho-
resis and subjected to fragmentation for 35 min. at 94uCi n
fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM
CH3COOH, 30 mM Mg(CH3COO)264H2O).
GeneChip microarray analysis and data normalization -
Labeled cRNA was used for screenings of GeneChip Human
Genome U133plus2 arrays (Affymetrix, Santa Clara, CA, USA).
Hybridization and scanning was performed on the Affymetrix
platform [32]. Data were preprocessed following the RMA
procedure of Bioconductor 2.8 using quantile normalization
(http://www.bioconductor.org). All microarray data is MIAME
compliant. The dataset, corresponding to 29 uveal melanoma
primary tumors is available from the GEO database (http://www.
ncbi.nlm.nih.gov/geo/), under accession number GSE27831.
RT-PCR analysis
cDNA was synthesized with oligo dT primers from 2 micrograms
of total RNA with Superscript II (RT Invitrogen). For conventional
RT-PCRtwomicrolitersofcDNAwereamplified with2.5IUofTaq
Polymerase (Roche), by using the following primers: Human SDCBP
upper primer: 59TGG TGG CTC CTG TAA CTG GTA A, lower
primer: 39TGC ATG GTA ATC GTC CGT TCA A. Human
ACTB upper primer: 59GTG GGG CGCCCCAGG GGCACC A,
lower primer: 59CTC CTT AAT GTC ACG CAC GAT TTC.
qPCR was performed on LightCycler480 II (Roche Applied
Science) using 10 ml of LightCycler 480 SYBR Green I Master
(Roche Applied Science), 2 ml of cDNA (56diluted), 0.3 mmol
sense and antisense primers in a final reaction volume of 20 ml.
After amplification, melting curves with 65 steps of 15 s and 0.5uC
increase were performed. Expression data were normalized on the
mean of GAPDH gene expression data. Relative expression values
were obtained using Qgene software. GAPDH upper primer: GAA
GGT GAA GGT CGG AGT, lower primer: CAT GGG TGG
AAT CAT ATT GGA A.
Immunostaining
Immunostaining of cultured cells or frozen sections of uveal
melanoma tumors derived patients and mice was performed using
the rabbit anti-mda-9/syntenin antibody ab19903 (1:100Abcam,
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4% paraformaldehyde (PFA) and incubated with the appropriate
antibody in PBS, 0.3% Triton X100 and 10% FBS. Binding of
primary antibodies was revealed with appropriate secondary
DyLight 488 affiniPure Goat Anti-Rabbit IgG (H+L) Jackson
Immunoresearch laboratories, USA. Nuclei were stained by
5 minutes incubation in Propidium Iodide solution (100 ng/ml).
To determine cytoplasmic and/or nuclear localization of mda-9/
syntenin slides were examined using a laser-scanning FV500
microscope equipped with 488, 543 and 633 nm lasers, and
coupled to an inverted IX81 platform (all from Olympus Optical,
Tokio, Japan). Digital images were acquired with Fluoview 4.3b
software.
Immunoblot analysis
Cells were lysed in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1% NP40) containing protease inhibitors (Com-
plete C Mini, Roche Applied Science, Indianapolis, IN) and
1 mM sodium orthovanadate. Nuclear extracts were prepared
with Nuclear Extract Kit (ACTIVE MOTIF) USA, following
manufacturer’s instructions. Cell lysates were then quantified using
the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). A standard
Western blot analysis was then performed. Briefly, 50–100 mgo f
each sample were run on 10% polyacrylamide gel. Gel was then
blotted to nitrocellulose membranes (Hybond-C Extra, Amersham
GE Healthcare, Little Chalfont, UK) according to standard
procedures and stained with antibodies to mda-9/syntenin,
HDAC1, Actin (Sigma-Aldrich), anti-FAK(pY
397), anti-Src
(pY418) and anti-Src pan (Invitrogen), and anti-FAK (Cell
Signaling), anti-phospho-AKT (Ser473), anti-AKT (pan), anti-
phospho-MET (Tyr1234/1235) and anti-MET (L41G3) (Cell
Signaling). Bands were visualized by a standard chemilumines-
cence method (Amersham ECL Plus, GE Healthcare, Little
Chalfont, UK). Band intensity was evaluated by densitometric
analysis with the KODAK ID image analysis software (Kodak,
Rochester, NY). Intensity of phosphorylated bands was normal-
ized to the correspondent unphosphorylated band.
FACS analysis
Cell were stained after permeabilization with anti-mda-9/
syntenin antibody and anti-c-MET (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), washed and incubated with DyLight 488
affiniPure Goat anti-rabbit secondary antibody. Cell fluorescence
was analyzed in a FACScan (Becton&Dickens).
Immunohistochemistry
Immunohistochemical (IHC) detection of mda-9/syntenin was
performed on formalin-fixed, paraffin-embedded sections from 29
enucleated primary uveal melanomas with known clinical history
(Table 1) and on three liver metastases. For each sample the more
representative tumor sections (3 mm) were immunostained using a
BenchMark XT automated stainer (Ventana Medical Systems, SA
Strasbourg France). The sections were deparaffinized and antigen-
retrieval was performed with high pH citrate buffer. The primary
antibody was used at 1:200 dilution of a commercially available
anti-mda-9/syntenin rabbit polyclonal antiserum (Abcam, Cam-
bridge) for 30 min at 37uC. The antibody complex was revealed
with the Polymeric System (Ultraview Red Ventana Medical
System/Alkaline phosphatase) and the Amplification Kit (Ventana
Medical System). Then the sections were counterstained with
modified Gill’s hematoxylin and mounted in Eukitt (Bio-Optica,
Milano, Italy). An appropriate positive tissue control was used for
each staining run; the negative control consisted of immunohis-
tochemistry procedure on adjacent sections in the absence of the
primary antibody. The sections were observed with an Olympus
light microscope using 610, 640 and 663 objectives. The
immunostaining was independently evaluated by two experienced
pathologists using a previously reported semi-quantitative scoring
system [34]. The extent of positively labeled cells was ranked into 5
grades, i.e. 0=0%, 1=1–10%, 2=11–50%; 3=51–90% and
4=.90%; staining intensity was graded into 4 steps with 0=no
staining; 1=low; 2=moderate and 3=strong staining. Results
were presented as product of the two assessments thus ranging from
0 to 12. Patient samples were then classified into two categories that
expressed mda-9/syntenin higher or lower than the median value.
Survival and statistical analysis
Disease-free survival curves were constructed by using the
Kaplan-Meier method and the Wilcoxon log-rank test was used
to compare the curves. Disease Free Survival (DFS) was defined as
the elapsed interval from date of eye removal or biopsy to date of
last follow-up or melanoma-related metastasis. Statistical analysis
was performed using Prism 5 (Graph-Pad Software, San Diego,
Ca, USA). All other data were compared using the Student’s t-test,
and a p-value,0.05 was considered statistically significant.
Small Interfering RNA (siRNA) transfection and wound-healing
and invasion assays.
ON-TARGET plus SMART pool for human SDCBPor
siCONTROL Non-Targeting siRNA pool (Dharmacon, Lafay-
ette, CO) were transfected in 92.1 and Mel270 cells using
Interferin, polyplus transfection (Invitrogen) following the the
manufacturer’s instructions. Efficiency of siRNA inhibition was
evaluated at the protein level by western blot analysis.
Transfected cells were assayed in a wound-healing assay to
assess cell motility in two dimensions. Cells were plated overnight
to achieve a subconfluent cell layer in 24 well-plates. A scratch was
made on the cell layer with a micropipette tip, and floating cells
were removed by two washes with serum-free medium. Cells were
then incubated in culture medium and ‘Wound-healing’ was
visualized by comparing photographs taken at the time of
scratching and 24 hours later, by a Nikon DS-5M Camera System
mounted on a phase-contrast Leitz microscope. The distance
migrated by the cells was determined by measuring the wound
width after 24 hours, and subtracting it from the wound width at
time 0. Three experiments were performed in quadruplicates.
BD BioCoat invasion chambers coated with growth factor
reduced Matrigel were purchased from BD Biosciences (Sparks,
MD) for invasion assays. One hundreds thousand cells diluted in
0.5 ml of medium containing 0.1% FCS were added to the top
chambers of 24-well transwell plates (BD Biosciences; 8- mm pore
size), and assay media, with or without 100 ng/ml of recombinant
HGF (Peprotech) or 10% FCS or 50% MG63 supernatant were
added to the bottom chambers. HGF-containing conditioned
medium of the MG63 cell line was kindly provided by Dr. Daniela
de Totero, IST Genova. After 48 hours incubation, top (non-
migrated) cells were removed, and bottom (migrated) cells were
fixed and stained with 1% toluidine blue to visualize nuclei. The
number of migrating cells in five fields were counted under 6200
magnification, and the mean for each chamber determined.
Experiments were run in triplicate.
Gain of function experiments
The full length human SDCBP cDNA fragment was amplified by
RT-PCR from 92.1 cells and cloned into eukaryotic expression
vector pIRESneo (Clontech). Correct nucleotide sequence of
SDCBP-cDNA was confirmed by sequencing (BigDyeH Terminator
v3.1 Cycle Sequencing Kit, Applied Biosystem and 3130XL, Life
Technology). Recombinant plasmid pIRESneo-SDCBP or empty
Mda-9/Syntenin and Uveal Melanoma Metastasis
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reagent (Invitrogen). After 48 hours transfected cells were lysed and
cytoplasmic extracts were analyzed on western blots.
In vivo experiments
The animals were housed in pathogen-free conditions. The
experiments were performed according to the National Regulation
on Animal Research Resources and approved by the Istitutional
Review Board for animal experimentation (Approval ID Number:
IST 284). All mice used in the study were anesthetized with intra-
peritoneal injections of ketamine and xylazine. For the induction
of liver metastases, 92.1-luciferase gene-transduced (luc) or Mel
270-luc melanoma cells (10
7–10
6 cells in 100 ml) were implanted
under the spleen capsule of six NU/NU mice (4–8 weeks old from
Janvier, France), and nine NOD/SCIDIL2Rc null mice (Jackson
Laboratory (Bar Harbor, ME). Mice were inspected at weekly
intervals by the IVIS (IVIS imaging 100, Xenogen, Caliper
LifeSciences, France), after intraperitoneal injection of 150 mg/kg
of luciferine, Promega Italia, Milano. Mice underwent necropsy 9
to 43 days later, when tumor outgrowth into the liver was clearly
evident. Part of the livers and spleens were frozen in liquid
nitrogen for immunohistochemical studies. Macroscopic metastat-
ic foci and primary tumors were also aseptically isolated and
cultured in complete medium for short term to evaluate mda-9/
syntenin expression by immunofluorescence.
Results
High level of SDCBP expression in primary uveal
melanomas and cell lines
In the search for new potential molecular pathways of
progression, we have performed gene expression profiling using
high-density microarrays of 29 primary uveal melanomas. SDCBP
Table 1. Clinicopathological characteristics of patient samples and expression of mda-9/syntenin by immunohistochemistry.
Specim. n Gender
Age at
proced.
Thickn.
(mm)
Largest
diamet.
(mm) Location Cell type Sclera Met
DFS
months Chr 3 Chr 8
Previous
Treatment
mda-9/
syntenin
MU_1 m 78 7 6 anterior spindle y n 67 d p none L
MU_10 m 84 14 25 anterior mixed y y 21 m d none H
MU_11 f 61 10 14 middle mixed n n 55 m d proton beam L
MU_12 f 74 5 10 middle mixed nd n 41 m p proton beam H
MU_13 m 70 16 17 middle epithelioid n n 55 d d none H
MU_15 m 74 6 13 posterior epithelioid n y 33 m p proton beam H
MU_17 m 60 9 11 posterior epithelioid n n 52 d d none L
MU_2 f 82 3 2 anterior spindle y n 20 m p proton beam L
MU_22 m 74 7 17 middle NP n n 40 d d proton beam H
MU_25 m 33 7,56 15 middle spindle y n 15 d d none L
MU_3 m 64 15 23 middle mixed y y 31 m d none H
MU_30 f 65 NP 15 middle NP y n 36 m na none H
MU_31 f 69 4,9 16 posterior mixed y y 17 m p none H
MU_32 f 76 5,3 12 posterior mixed y n 44 d d none L
MU_33 m 59 5,2 14 middle spindle y n 43 m d none L
MU_34 m 51 10,5 15 middle mixed y y 19 m p none H
MU_36 m 80 16 12 middle epithelioid n y 19 m p none L
MU_4 m 61 6 11 posterior spindle n y 31 m d none H
MU_40 m 51 NP 16 NP epithelioid y n 40 m d none L
MU_5 m 85 12 16 middle spindle y n 48 d d none H
MU_6 m 48 8 12 middle mixed n n 57 d d none L
MU_7 f 69 13 12 anterior epithelioid n y 25 m p none H
MU_8 f 74 7 9 middle mixed n y 18 d d none H
MU_9.1 m 66 6 14 middle mixed n y 17 m p none L
MU16 f 77 7 9 posterior mixed n n 54 d d none L
MU18 m 62 4 20 posterior spindle y n 41 m d none L
MU20 f 55 11 13 middle spindle n n 48 d d none L
MU21 f 42 10 12 posterior mixed n y 51 m p none H
MU23 f 71 NP 16 NP spindle y n 42 m d Proton
beam
L
Met: metastasis; Chr: chromosome; DFS: disease free survival. nd: not done; NP: not provided. In the eleventh column m: monosomy; d: disomy. In the twelft column p:
polisomy; d: disomy. In the thirteenth column: previous patients treatment. In the fourteenth column: mda-9/syntenin expression level, L: low expression; H: high
expression.
doi:10.1371/journal.pone.0029989.t001
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levels (Fig. 1 A). Differently, the genes of syndecans (SDC 1, 2, 3
and 4) were expressed at relatively low levels, although SDC2
showed higher expression than the other members of the same
family in nine patients (Fig. 1B). Notably, syndecan binding
protein-2 (SDCBP2) was not expressed in any of the samples tested
(Fig. 1B).
Eleven patients out of 29 developed liver metastases during
follow-up (on average after 36.7 months, range 15 to 67 months).
High SDCBP mRNA expression conferred a risk with Odds Ratio
of 9.0 (p=0.01, IC 95% 1.46–55.48) for recurrence, which was as
strong as monosomy 3 (OR: 12.50, p=0.01, IC 95% 1.31–
119.33), in our cohort. Both monosomy 3 and SDCBP overex-
pression significantly correlated with the occurrence of metastasis
(monosomy r=0.46 p=0.01, SDCBP r=0.47, p=0.001). The
differential expression of SDCBP between metastatic and non-
metastatic patients (median 9484 as compared to 8330 as average
of normalized intensity values) showed a trend to statistical
significance (P=0.07) in our cohort (Fig. 1 C). It must be
emphasized that our cohort had a rather short follow-up
(maximum 67 months) and that the number of metastatic patients
was lower (37.9%) than that expected (50%) at a longer follow-up,
possibly limiting the achievement of statistical significance.
Therefore, to further evaluate the possible correlation of SDCBP
expression with high metastatic risk, we analyzed the expression
profile of another cohort of 27 patients with a longer follow-up,
kindly provided by Dr Onken. A molecular signature predictive of
metastatic progression and death, was previously identified in this
cohort by the authors [13]. Since SDCBP gene expression was not
addressed in this previous study, we analyzed their raw data for
SDCBP, with the aim to corroborate our findings on a different
cohort. Expression of SDCBP was significantly higher (p=0.009) in
class-2 (high risk) than in class-1 (low risk) cases (Fig. 1D), according
to the classification proposed by the authors. In addition, when the
Onken classifier was applied to our microarray data, we found that
all metastatic patients, but one, fell in the high-risk class. Moreover,
SDCBP was found to be expressed at a significantly higher level
(p=0.015) in metastatic compared to non-metastatic patients in an
additional gene expression profile dataset of 63 uveal melanoma
patients (Fig. 1E), recently reported by Laurent et al [35].
We further analyzed SDCBP expression in human uveal
melanoma cell lines and primary cultures derived from four
primary uveal melanomas, (fig. 2A). MEL 270 and 92.1 cell lines,
which derive from primary tumors, and OMM1 and OMM2.5
deriving from skin and liver metastases, respectively [30–31]
clearly expressed SDCBP, thus confirming that SDCBP is expressed
by uveal melanoma neoplastic cells. qPCR analysis showed that
SDCBP gene expression was higher in the 92.1 than in MEL 270
cell lines and in the OMM2.5 hepatic metastasis than in the
OMM1 cutaneous metastasis cell line. Of note, the OMM2.5
Figure 1. Gene expression profile of primary uveal melanomas reveals high but heterogeneous expression of SDCBP.A :Bars indicate
intensitiy of SDCBP expression in 29 primary uveal melanoma analyzed by gene expression profiling in the present study. B: Heat map showing the
expression levels of syndecan (SDC)-1, -2, 3 and -4 genes, SDCBP and syntenin-2 (SDCBP2). C: Comparrison of SDCBP expression in metastatic and non-
metastatic patients (n=29) in our cohort showed a trend to higher SDCBP expression in metastatic patients (p=0.07). The same type of comparison
performed on gene expression profile data from Onken et al. (D), between class1 (low-risk) and class 2 (high risk) patients (n=27) [13] and on gene
expression profile data from Laurent et al. (E) between metastatic and non-metastatic patients (n=63) [35] showed significantly elevated levels of
SDCBP in high risk and metastic patients, respectively.
doi:10.1371/journal.pone.0029989.g001
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primary tumor cell line, derived from the same patient [36]. A
certain degree of heterogeneity of SDCBP expression was also
observed in primary cultures (Fig. 2B).
Analysis of mda-9/syntenin protein expression in uveal
melanoma
Mda-9/syntenin protein expression was first confirmed by
immunofluorescence on cultured cells. Figure 3 shows that mda-9/
syntenin protein is present in all the four uveal melanoma cell lines
and in the four primary cultures. Interestingly, mda-9/syntenin
seemed localized not only in the cytoplasm but also in the nucleus,
particularly in the 92.1 and OMM2.5 cell lines. Indeed, confocal
microscopy showed localization of mda-9/syntenin protein both in
the cytoplasm and in the nuclei of 92.1 and OMM2.5 cells
(Figure 4A and Figure S1). The nuclear and cytoplasmic
expresssion of mda-9/syntenin was further confirmed by western
blot analyses performed on cytoplasmic and nuclear extracts of
uveal melanoma cell lines, with the strongest nuclear expression in
92.1 and OMM2.5 cells (Figure 4B). Therefore the pattern of
mda-9/syntenin localization in uveal melanoma cells seemed
different from the cytoplasmic and sub-membrane expression
previously reported in cutaneous melanoma.
Mda-9/syntenin expression was then analyzed in sections of the
primary tumors from our cohort and of three metastatic livers by
immunohistochemistry. All primary tumors analyzed showed
staining with anti-mda-9/syntenin antibodies, although with
different intensities. Tumor sections from three representative
cases showed low, medium or high levels of mda-9/syntenin (Fig. 5
B, C and D, respectively). A choroidal metastasis of colon
adenocarcinoma was completely negative for mda-9/syntenin
(Fig. 5A), confirming the specificity of staining in uveal
melanomas. Fifteen tumors were classified as high-mda-9/syntenin
and fourteen as low-mda-9/syntenin on the basis of a scoring
system taking into account both overall intensity and percentage of
positive cells ([34] and Material and methods). Nine patients with
high-mda-9/syntenin tumors developed metastatic progression,
while among the fourteen patients of the mda-9/syntenin-low
group only two developed metastasis. High syntenin protein
expression conferred a risk with Odds Ratio of 11.70 (p=0.005,
IC 95% 1.85–74.19). In addition, Kaplan-Meier analysis showed
that the high-mda-9/syntenin phenotype is significantly (p=0.014)
related to relapse (Fig. 5 panel I), suggesting its potential role as a
marker of progression. Also in tumor sections, different degrees of
nuclear expression, ranging from very few cells to .90% of cells,
were evident (Figure S2). The nuclear score of mda-9/syntenin
seemed not related to progression (p=ns by Kaplan-Meier
analysis, data not shown), although the trend was towards high
expression cases showing an increased risk.
The SDCBP gene is located on the long arm of chromosome 8
(8q12.1), which is often amplified in high-risk patients. However,
no significant correlation was found between mda-9/syntenin
overexpression either as mRNA or protein, and amplification of
the long arm of chromosome 8. Interestingly, mda-9/syntenin
protein was also very strongly expressed on three liver metastases
(two of which are shown in figure 5 E–H). Staining for mda-9/
Figure 2. SDCBP mRNA is expressed in uveal melanoma cells. A: Conventional RT-PCR analysis of SDCBP gene expression in cell lines derived
from primary tumors (MEL 270 and 92.1), cell lines derived from metastatic lesions (OMM1 and OMM2.5) and from four primary cultures derived from
patients’ ocular tumors (1,2,3,4). The lane identified by ‘‘C-’’ indicates negative control in the absence of cDNA. B: qPCR analysis of SDCBP mRNA
expression in uveal melanoma cell lines and primary cultures. Expression values are normalized on the mean of GAPDH gene expression.
doi:10.1371/journal.pone.0029989.g002
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liver parenchyma, which was completely negative for mda-9/
syntenin-1 expression (Fig. 5 F,H, arrows).
Overexpression of mda-9/syntenin in liver metastases of
uveal melanoma xenograft models
Data from gene expression profiling and immunohistochemistry
suggested the hypothesis that mda-9/syntenin could be related to
an invasive behavior of uveal melanoma cells. To further test this
hypothesis we developed a pseudo-metastatic xenotransplant
model of human uveal melanoma in immunodeficient mice. The
spleen was chosen for tumor cell implantation because in this site
tumor cells have access to the portal vein circulation and will have
a greater likelihood of forming liver metastases. Indeed, liver
metastases were detected by IVIS analysis at 40 days on average,
(range 30–70) after intrasplenic inoculation of 92.1 or Mel 270 luc
cells in all (6/6) nude mice. Moreover, NOD/SCIDIL2Rc null
mice (9/9) developed liver metastases detectable at IVIS analysis
as soon as 20 days on average (range 14–23) after intrasplenic
injection. This earlier development of metastases in the NOD/
SCIDIL2Rc null mice (Figure S3) is likely related to a more
profound immune defect and to the lack of NK cells in this strain
of mice [37].
The expression of mda-9/syntenin was then studied in frozen
sections of spleen and liver of transplanted mice by immunohis-
tochemistry. Mda-9/syntenin immunostaining appeared moderate
in spleen tumors, the primary site of implant, though single cells
showed a bright staining (Fig. 6 A). Metastatic lesions, instead,
stained more intensely for mda-9/syntenin (Fig. 6A) than the
splenic tumor, whereas the normal hepatic tissue was negative. To
Figure 3. Analysis of Mda-9/syntenin protein expression in
uveal melanoma cell lines. A: Immunostaining of fixed and
permeabilized cell lines (left) and primary cultures (right). Original
magnification 4006. The insets show the negative control performed by
the use of non-immune rabbit Ig.
doi:10.1371/journal.pone.0029989.g003
Figure 4. Mda-9/syntenin is expressed in the nucleus of uveal
melanoma cells. A: Confocal fluorescence microscopy shows nuclear
and cytoplasmic localization of mda-9/syntenin in 92.1 cells (upper
panels) and OMM2.5 cells (lower panels). An optical section with mda-9/
syntenin staining (green) and propidium iodide (red) is shown. A
merging image is shown in the bottom quadrants of each panel
(original magnification 6006). B: Western blot analysis showing nuclear
and cytoplasmic expression of mda-9/syntenin. HDAC1 and b-actin
were used as loading controls for nuclear and cytoplasmic extracts,
respectively.
doi:10.1371/journal.pone.0029989.g004
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metastases compared to the primary tumors, tumor cells were
obtained from both tumor lesions, grown in vitro for a few days
and analyzed by cytofluorimetric analysis. As shown in Fig. 6B the
mda-9/syntenin expression was significantly higher in the cells
from liver metastases than in cells derived from the splenic tumor
(mean fluorescence intensity was 1.9260.343-fold higher in liver-
derived cells than in spleen-derived cells, p=0.0096). The
expression level of the CD44 molecule was unchanged in both
cell populations (data not shown).
Figure 5. Immunohistochemical analysis of mda-9/syntenin in
tissue sections of primary uveal melanomas shows correlation
with metastatic progression. A: mda-9/syntenin expression in a
choroidal metastasis of colon adenocarcinoma A9: primary uveal
melanoma stained by secondary antibody in the absence of anti-
mda-9/syntenin antibody (negative control). B, C, D: representative
primary uveal melanomas displaying low, medium or high levels of
mda-9/syntenin expression, respectively (original magnification 4006).
E: liver metastasis of uveal melanoma (original magnification 1006). F:
the same section at higher magnification (2006). Arrows indicate single
cells of UM positive for mda-9/syntenin, which infiltrate the mda-9/
syntenin-negative liver parenchima. G: liver metastasis of uveal
melanoma from a different patient. H: the same at higher magnifica-
tion. I: Kaplan-Meier analysis of Mda-9/syntenin protein expression and
disease-free survival in patients with primary tumors. Patients with low
mda-9/syntenin expression (dark line) showed longer survival than
patients with high expression (gray line) (P,0.014). Patients were
stratified according to a combination of qualitative/semi-quantitative
grading. Censored patients are indicated in each curve.
doi:10.1371/journal.pone.0029989.g005
Figure 6. Mda-9/syntenin expression in a pseudo-metastatic
model of uveal melanoma obtained by injection of human 92.1
cells under the spleen capsule of NOG mice: mda-9/syntenin
expression is higher in liver metastases than in spleen. A:
Immunohistochemistry of murine splenic uveal melanoma and liver
metastases (Original Magnification 4006). Arrows indicate single cells of
uveal melanoma strongly positive for mda-9/syntenin present in the
spleen; arrowheads indicate mda-9/syntenin positive metastatic cells in
the liver. B: Flow-cytometric analysis of intracellular mda-9/syntenin
expression in permeabilized 92.1 cell derived from splenic tumor and
liver metastases, C- is the negative control.
doi:10.1371/journal.pone.0029989.g006
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invasiveness
To assess the possible role of mda-9/syntenin in uveal melanoma
metastatic process we silenced SDCBP expression by siRNA in 92.1
and Mel 270 cells with siRNA and studied the effects on cell
migration. Western blot of the two cell lines, treated with SDCBP
targeting siRNA, demonstrated over 80% reduction of the mda-9/
syntenin protein expression compared to the cells treated with
scrambled siRNA (Fig. 7A). As shown in Fig. 7B, the inhibition of
mda-9/syntenin expression in Mel270 and 92.1 cells impaired their
ability to migrate in a wound–healing assay. The inhibition of
migration was statistically significant in both Mel 270 (p=0.028)
and 92.1 (0.019) cells (Fig. 7, C and D respectively).
We further studied the role of mda-9/syntenin-1 using an
invasion assay based on a transwell device in which the two
chambers are separated by a matrigel-coated porous set. The
MG63 cell conditioned medium, which contains HGF [38], or
recombinantHGFwereusedasstimulus,asHGFhasbeeninvolved
in uveal melanoma migration or invasion [5–7]. The 92.1 cell line,
which expresses high levels of mda-9/syntenin and the HGF
receptor c-MET (Figure 8A) invaded the matrigel membrane in
response to MG63 conditioned medium or to recombinant HGF
(Figure 8B). SDCBP silencing significantly inhibited invasion
triggered by both stimuli (Figure 8C). These results indicate that
mda-9/syntenin is involved in uveal melanoma cell migration and
in their invasiveness triggered by HGF stimulation.
Mda-9/syntenin is known to promote cell motility and invasion
by connecting surface integrin signals to FAK activity [28]. In
addition, signaling via c-MET is known to activate FAK activity
[39], although a role of mda-9/syntenin in this pathway has not
been established. We therefore studied the influence of mda-9/
syntenin silencing on FAK phosphorylation in response to
recombinant HGF. Treatment of 92.1 cell with recombinant
HGF for 10 min clearly increased FAK phosphorylation at Tyr397,
while total FAK levels were unchanged (Fig. 8D). Silencing the
expression of SDCBP by siRNA strongly inhibited constitutive and
HGF induced Fak phosphorylation (45 and 50% respectively)
(Fig. 8D). In addition, mda-9/syntenin silencing also partially
inhibited constitutive and/or HGF-promoted Src (15 and 30%
respectively) and AKT phosphorylation (20%) in 92.1 cells (Fig. 8D)
without affecting neither c-MET expression nor its phosphorylation
(Fig. 8E).
Overexpression of mda-9/syntenin-1 increases
invasiveness
We further studied the effects of mda-9/syntenin overexepres-
sion in gain-of-function studies through SDCBP gene transfection
in the low-expressing Mel 270 cell line. Also this cell line expressed
c-MET (Fig. 9A). SDCBP-transfected Mel 270 expressed approx-
imately 40% higher mda-9/syntenin levels (Fig. 9C) and showed
increased invasiveness in response to HGF across matrigel-coated
porous membranes (Fig. 9B) compared to mock-transfected cells
Figure 7. Silencing of SDCBP by siRNA inhibits uveal melanoma cell migration. A: Western blot analysis of MEL 270 and 92.1 cell lines upon
72 hrs treatment with scrambled siRNA (C), and SDCBP targeting siRNA (Synt). B: wound-healing assay on MEL 270 and 92.1 cell lines treated with
scrambled siRNA (C) or with SDCBP targeting siRNA (Synt). Mean of migration distance of MEL 270 cells (C) and 92.1 (D) treated with scrambled siRNA
(black bars) or with SDCBP targeting siRNA (grey bars), P values are indicated.
doi:10.1371/journal.pone.0029989.g007
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cells resulted in increased FAK (20%), and Src (30%) phosphor-
ylation in response to HGF stimulation (Fig. 9C), while the effect
on AKT activation was modest.
Altogether, loss- and gain-of-function studies suggest that mda-
9/syntenin is involved in the activation of an invasive program
mediated by HGF in uveal melanoma cells.
Discussion
Our results provide the first evidence that mda-9/syntenin is
expressed in human uveal melanoma and that high level of
expression of mda-9/syntenin conferres a high risk of metastatic
recurrence. In addition, our present study suggests a role of mda-
9/syntenin in promoting metastatic spreading in this tumor.
Recent findings have demonstrated that the high expression of
mda-9/syntenin is related to the metastatic potential of breast and
gastric cancer [27] and cutaneous melanoma cells [25]. The
possible role of mda-9/syntenin expression and metastatic
progression was demonstrated in cutaneous melanoma, where
mda-9/syntenin, through interaction with c-Src/FAK, activates
the p38 MAPK/NFkB pathway with subsequent induction of
genes involved in migration and invasion [28]. In the present
study, a correlation of high SDCBP gene expression with metastatic
progression was suggested by the analysis of the gene expression
profile of 29 primary uveal melanomas. Indeed we found that high
Figure 8. Silencing of mda-9/syntenin in 92.1 uveal melanoma cells inhibits in vitro invasion and HGF mediated signaling. A:
Expression of c-MET in 92.1 cells detected by indirect immunofluorescence and flow-cytometry; c: negative control. B: Invasion of matrigel
membranes by 92.1 cells towards different stimuli: medium with 10% serum (C), 50% conditioned medium from MG63 cell line (CM), 100 ng/ml
recombinant HGF in 0.1% serum. C: Silencing of SDCBP (Synt-siRNA) in 92.1 cells inhibits their ability to invade matrigel membranes in response to
conditioned medium from MG63 cell line (CM) or recombinant HGF (100 ng/ml). Data are presented as percentage of invading 92.1 cells treated with
scrambled siRNA (C-siRNA). * p,0.04. D: Western blot showing inhibition of FAK, AKT and Src phosphorylation in SDCBP-silenced 92.1 cells compared
to cells treated with scrambled siRNA. The same membrane was also stained for unphosphorylated FAK, AKT and Src , mda-9/syntenin and b-actin as
protein loading control. E: Silencing of mda-9/syntenin in 92.1 uveal melanoma cells does not effect c-MET expression and p-MET phosphorylation.
Western blot analysis of c-MET, p-MET, mda-9/syntenin and and b-actin as protein loading control in in 92.1 SDCBP silenced cells and control siRNA.
doi:10.1371/journal.pone.0029989.g008
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metastatic recurrence (Odds ratio of 11.70 p,0,005) in our
cohort. The correlation of SDCBP mRNA levels with recurrence
was further confirmed by the analysis of the raw data of two
previously reported [13,14,35] datasets of 27 and 63 primary uveal
melanomas, respectively. Interestingly, we observed that high
expression of SDCBP is related to the class 2-gene signature, which
has been associated with metastatic behavior of uveal melanoma.
It is of note that the top discriminating genes in the previously
reported signature were down-regulated genes, whereas SDCBP is
up-regulated in progressing tumors. Although SDCBP maps to
8q12.1, we could not find a significant correlation between
chromosome 8 amplification and SDCBP gene or protein
expression. This may be due either to a partial amplification of
SDCBP below resolution limit of FISH, or to other mechanisms
up-regulating SDCBP transcription or mRNA stability. Interest-
ingly, expression of the PTP4A3 gene mapping on chromosome 8
(8q24.3), has been recently related to uveal melanoma metastatic
behavior, and also in this case no correlation with chromosome 8
amplification was found [35].
The immunohistochemical analysis of archival tumors of 29
patients showed expression of mda-9/syntenin protein in all
samples, and also higher expression in nine out of eleven metastatic
patients analyzed. It is of note that a high level of mda-9/syntenin
protein in primary tumors was significantly related to earlier
metastatic progression although, further studies involving larger
groups of patients are needed to confirm this possibility. Thus, mda-
9/syntenin protein, which can be easily detected by immunohisto-
chemistry, correlates with metastatic risk as strongly as monosomy
3 and may represent a candidate prognostic marker of uveal
melanoma. Besides the value of mda-9/syntenin expression as
prognostic marker in primary tumors, immunohistochemistry of
threelivermetastasesofuvealmelanomashowedaverystrongmda-
9/syntenin staining, suggesting a role of mda-9/syntenin in the
metastatic process.
Intriguingly, we also found that mda-9/syntenin is localized not
only in the cytoplasm but also in the nuclei of uveal melanoma
cells of cell lines or tumor specimen. A noticeable heterogeneity of
nuclear localization was observed in different samples. When the
intensity of mda-9/syntenin-positive nuclei was considered, no
significant relationship with clinical course was evident. Though
the possible role of mda-9/syntenin in nuclear functions has yet to
be determined in uveal melanoma, recent findings indicated that
mda-9/syntenin colocalizes with the SOX-4 transcription factor in
the nucleus and stabilizes its expression in different tumor cells
[40].
To further study the role of SDCBP in uveal melanoma
metastases, we developed a pseudometastatic model obtained by
intrasplenic injection of uveal melanoma cell lines. The NOD/
SCIDIL2Rc null mice, which in addition to the other immune
Figure 9. Overexpression of mda-9/syntenin in Mel 270 uveal melanoma cells increases HGF-mediated signaling and invasiveness.
A: Expression of c-MET in Mel 270 cells detected by indirect immunofluorescence and flow-cytometry; c: negative control. B: Transfection of SDCBP
(SDCBP+) in Mel 270 cells enhances their ability to invade matrigel membranes in response to recombinant HGF (100 ng/ml). Data are presented as
number of invading cells transfected with mda-9/syntenin vector or empty vector (mock). *: statistically significant difference between HGF induced
invasion of mda-9/syntenin and mock transfected cells, p,0.04. C: Western blot analysis of FAK, AKT and Src phosphorylation in SDCBP-transfected
Mel 270 cells compared to mock-transfected cells. The same membrane was also stained for unphosphorylated FAK, AKT and Src, mda-9/syntenin and
b-actin protein as loading control. The second lane was cropped and repositioned.
doi:10.1371/journal.pone.0029989.g009
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allowed a more rapid development of liver metastases than nude
and NOD-SCID mice. This finding suggests that NK cells present
in the latter strains may partially counteract metastatic dissemi-
nation to the liver, suggesting that not only human [36] but also
mouse NK cells are able to recognize human uveal melanoma
cells. Moreover, our in vivo model of pseudo-metastatic tumor
showed a higher expression of mda-9/syntenin in the liver
metastases as compared to the spleen, the primary site of injection.
A possible explanation of this finding is that tumor cells with the
highest expression of mda-9/syntenin are more prone to migrate
from the primary tumor and subsequently metastasize. This
hypothesis would corroborate the finding of a worse prognosis for
those patients expressing high levels of mda-9/syntenin in the
primary tumor. Alternatively the liver microenvironment could
stimulate mda-9/syntenin expression on the metastatic cells.
However, incubation of human uveal melanoma cell lines with
mouse liver extracts did not increase mda-9/syntenin expression
(data not shown) suggesting that high mda-9/syntenin expressing
cells are more prone to metastasize. In addition, our present
observation that silencing of SDCBP by siRNA inhibits migration
and invasiveness of uveal melanoma cells, suggests that mda-9/
syntenin is involved in the metastatic dissemination. In this context
HGF and its receptor c-MET have been involved in tumor
invasiveness and metastatic progression in different types of tumors
[41], also including uveal melanoma [5–7]. A previous report
indicated that HGF enhances migration of uveal melanoma cells
[42] and our present study also indicate that the HGF/c-MET
axis plays a role in driving invasion. In addition, our data indicate
for the first time that mda-9/syntenin is involved in c-MET
triggering of invasion, as suggested by SDCBP silencing and gain-
of-function experiments. Regarding the molecular mechanisms
involved, we found that inhibition of mda-9/syntenin expression
reduces the activation of FAK, Src and AKT mediated by HGF,
whereas its overexpression has opposite effects. Previous data
indicated that, upon activation, c-MET can physically interact
with FAK, which is an essential kinase involved in the acquisition
of an invasive potential [39]. In addition, Mda-9/syntenin has
been involved in FAK activation by signals through fibronectin-
binding integrins through Src/FAK clustering in cutaneous
melanoma [28]. Further studies will be required to establish
whether similar molecular clustering mediated by mda-9/syntenin
could be involved in c-MET signaling. In conclusion, our present
data indicate that SDCBP mRNA and mda-9/syntenin protein
deserve further investigation as candidate prognostic markers of
uveal melanoma and as potential targets for novel therapies aimed
at blocking the metastatic process in this tumor.
Supporting Information
Figure S1 Nuclear and cytoplasmic localization of mda-
9/syntenin in uveal melanoma cell lines. Confocal
microscopy of 92.1 and OMM2.5 cells stained for anti- mda-9/
syntenin (green). Nuclei are stained with propidium iodide (red). Z-
Y and Z-X sections through a 3-dimensional stack of confocal
images show nuclear localization of mda-9/syntenin.
(TIF)
Figure S2 Nuclear and cytoplasmic localization of mda-
9/syntenin in primary uveal melanomas. Immunohysto-
chemistry of primary uveal melanoma specimens for mda-9/
syntenin showed prevalent nuclear (panel A) or cytoplasmic
localization (panel B) in different primary uveal melanomas.
(TIF)
Figure S3 Liver metastases develop earlier in NOD/
SCIDIL2Rc null mice (NOG) (upper panels), than in
nude mice (lower panels). NOG and NU/NU mice were
imaged with IVIS imaging system at different time points (15, 22
and 30 days) following spleen transplantation of 10
5 92.1 or Mel
270 transduced with a retroviral vector containing the luciferase
gene. The signal intensity in the region of interest (ROI) is shown
in each mouse.
(TIF)
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